The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Open accessAbstract
Purpose: Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development of MPN-directed therapies. We aimed to assess the utility of an abbreviated symptom score for the most pertinent and representative MPN symptoms for subsequent serial use in assessing response to therapy. Patients and Methods: The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) was calculated as the mean score for 10 items from two previously validated scoring systems. Questions focus on fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Results: MPN-SAF TSS was calculable for 1,408 of 1,433 patients with MPNs who had a mean score of 21.2 (standard deviation [SD], 16.3). MPN-SAF TSS results significantly differed among MPN disease subtypes (P < .001), with a mean of 18.7 (SD, 15.3), 21.8 (SD, 16.3), and 25.3 (SD, 17.2) for patients with essential thrombocythemia, polycythemia vera, and myelofibrosis, respectively. The MPN-SAF TSS strongly correlated with overall quality of life (QOL; r = 0.59; P < .001) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) functional scales (all P < .001 and absolute r ≥ 0.50 except social functioning r = 0.48). No significant trends were present when comparing therapy subgroups. The MPN-SAF TSS had excellent internal consistency (Cronbach's α = .83). Factor analysis identified a single underlying construct, indicating that the MPN-SAF TSS is an appropriate, unified scoring method. Conclusion: The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptom study to date. This new prospective scoring method may be used to assess MPN symptom burden in both clinical practice and trial settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Self-citation
Cited by
Nestin-expressing progenitor cells: function, identity and therapeutic implications
Bernal, A., & Arranz, L. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2794-z · Cited by 389
Vannucchi, A. M., Kantarjian, H. M., Kiladjian, J.-J., Gotlib, J., Cervantes, F., Mesa, R. A., Sarlis, N. J., Peng, W., Sandor, V., Gopalakrishna, P., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.119545 · Cited by 260
Self-citationHuberty, J., Eckert, R., Larkey, L., Kurka, J., Rodríguez De Jesús, S. A., Yoo, W., & Mesa, R. (2019) · JMIR Formative Research · doi:10.2196/12662 · Cited by 67
Self-citationChihara, D., Masarova, L., Newberry, K. J., Maeng, H., Ravandi, F., Garcia-Manero, G., Ferrajoli, A., Cortes, J., Kantarjian, H., & Verstovsek, S. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.06.007 · Cited by 21
Investigational Janus kinase inhibitors in development for myelofibrosis
Bose, P., Abou Zahr, A., & Verstovsek, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1323871 · Cited by 12
Metadata
- Authors
- Emanuel, R. M., Dueck, A. C., Geyer, H. L., Kiladjian, J.-J., Slot, S., Zweegman, S., te Boekhorst, P. A. W., Commandeur, S., Schouten, H. C., Sackmann, F., Kerguelen Fuentes, A., Hernández-Maraver, D., Pahl, H. L., Griesshammer, M., Stegelmann, F., Doehner, K., Lehmann, T., Bonatz, K., Reiter, A., Boyer, F., Etienne, G., Ianotto, J.-C., Ranta, D., Roy, L., Cahn, J.-Y., Harrison, C. N., Radia, D., Muxi, P., Maldonado, N., Besses, C., Cervantes, F., Johansson, P. L., Barbui, T., Barosi, G., Vannucchi, A. M., Passamonti, F., Andreasson, B., Ferarri, M. L., Rambaldi, A., Samuelsson, J., Birgegard, G., Tefferi, A., & Mesa, R. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-11-20
- Volume
- 30
- Issue
- 33
- Pages
- 4098-4103
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2141249732
- Cited by
- 457
- References
- 2
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. https://app.cochat.ai/papers/10.1200/jco.2012.42.3863
- The paper
- Emanuel, R. M., Dueck, A. C., Geyer, H. L., Kiladjian, J.-J., Slot, S., Zweegman, S., te Boekhorst, P. A. W., Commandeur, S., Schouten, H. C., Sackmann, F., Kerguelen Fuentes, A., Hernández-Maraver, D., Pahl, H. L., Griesshammer, M., Stegelmann, F., Doehner, K., Lehmann, T., Bonatz, K., Reiter, A., . . . Mesa, R. A. (2012). Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.42.3863
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
